AstraZeneca trumpets standalone strength in drug development

November 18, 2014 8:13 AM

4 0

AstraZeneca trumpets standalone strength in drug development

LONDON (Reuters) - AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

Flagging an "industry-leading" portfolio of immune-boosting cancer drugs, the company also brought forward the filing date for a new lung cancer pill and said it had the potential to win between eight and 10 new drug approvals in 2015-2016 across all disease areas.

Read more

To category page

Loading...